$QNCX
Quince Therapeutics, Inc.

2020 Q1 Form 10-Q Financial Statement

#000156459020024670 Filed on May 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.480M $1.250M
YoY Change 178.4% 257.14%
% of Gross Profit
Research & Development $14.38M $4.825M
YoY Change 198.03% 99.96%
% of Gross Profit
Depreciation & Amortization $80.00K -$10.00K
YoY Change -900.0% -200.0%
% of Gross Profit
Operating Expenses $17.86M $6.075M
YoY Change 193.96% 120.11%
Operating Profit -$17.86M -$6.075M
YoY Change 193.96% 120.11%
Interest Expense $680.0K $390.0K
YoY Change 74.36% -34.89%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$17.18M -$5.680M
YoY Change 202.46% 68.05%
Income Tax
% Of Pretax Income
Net Earnings -$17.18M -$5.681M
YoY Change 202.34% 68.23%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.61 -$0.22
COMMON SHARES
Basic Shares Outstanding 29.40M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $162.4M $59.04M
YoY Change 175.05%
Cash & Equivalents $85.61M $20.63M
Short-Term Investments $76.80M $38.41M
Other Short-Term Assets $954.0K $387.0K
YoY Change 146.51%
Inventory
Prepaid Expenses $164.0K $243.0K
Receivables
Other Receivables
Total Short-Term Assets $168.6M $63.79M
YoY Change 164.3%
LONG-TERM ASSETS
Property, Plant & Equipment $1.300M $314.0K
YoY Change 314.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $61.10M $5.400M
YoY Change 1031.48%
Other Assets $200.0K $261.0K
YoY Change -23.37%
Total Long-Term Assets $62.60M $6.806M
YoY Change 819.78%
TOTAL ASSETS
Total Short-Term Assets $168.6M $63.79M
Total Long-Term Assets $62.60M $6.806M
Total Assets $231.2M $70.60M
YoY Change 227.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.000M $1.946M
YoY Change 156.94%
Accrued Expenses $8.200M $1.724M
YoY Change 375.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.10M $4.010M
YoY Change 226.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.0K $500.0K
YoY Change -80.0%
Total Long-Term Liabilities $100.0K $500.0K
YoY Change -80.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.10M $4.010M
Total Long-Term Liabilities $100.0K $500.0K
Total Liabilities $13.20M $4.485M
YoY Change 194.31%
SHAREHOLDERS EQUITY
Retained Earnings -$38.51M
YoY Change
Common Stock $502.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $218.0M -$38.03M
YoY Change
Total Liabilities & Shareholders Equity $231.2M $70.60M
YoY Change 227.5%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$17.18M -$5.681M
YoY Change 202.34% 68.23%
Depreciation, Depletion And Amortization $80.00K -$10.00K
YoY Change -900.0% -200.0%
Cash From Operating Activities -$10.78M -$7.216M
YoY Change 49.38% 127.13%
INVESTING ACTIVITIES
Capital Expenditures $5.000K $51.00K
YoY Change -90.2%
Acquisitions
YoY Change
Other Investing Activities -$72.68M $51.32M
YoY Change -241.62%
Cash From Investing Activities -$72.68M $3.164M
YoY Change -2397.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 117.9M 64.00K
YoY Change 184043.75% -73.11%
NET CHANGE
Cash From Operating Activities -10.78M -7.216M
Cash From Investing Activities -72.68M 3.164M
Cash From Financing Activities 117.9M 64.00K
Net Change In Cash 34.39M -3.988M
YoY Change -962.39% 35.69%
FREE CASH FLOW
Cash From Operating Activities -$10.78M -$7.216M
Capital Expenditures $5.000K $51.00K
Free Cash Flow -$10.78M -$7.267M
YoY Change 48.4% 128.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
117690000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
191000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1955000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-97000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-32626000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
64000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
190000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
26000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-38027000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-17176000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-5681000
CY2020Q1 crtx Non Cash Rent Expense
NonCashRentExpense
92000
CY2019Q1 crtx Non Cash Rent Expense
NonCashRentExpense
92000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1955000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
190000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
83000
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
19000
CY2020Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-56000
CY2019Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
171000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-49000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3628000
CY2019Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
250000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1879000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1451000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2283000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
762000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10779000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7216000
CY2020Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
95543000
CY2019Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
25585000
CY2020Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
22867000
CY2019Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
28800000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
51000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-72681000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3164000
CY2020Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
29000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
191000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
64000
CY2020Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
117690000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
117852000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
34392000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3988000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51214000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24872000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85606000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20884000
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
122000
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
815000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as related disclosure of contingent assets and liabilities. The most significant estimates used in the Company&#8217;s financial statements relate to the determination of the fair value of common stock prior to the initial public offering, stock-based awards and other issuances, accruals for research and development costs, useful lives of long-lived assets, stock-based compensation and related assumptions, the incremental borrowing rate for leases and income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from the Company&#8217;s estimates.</p>
CY2020Q1 crtx Entity Date Of Incorporation
EntityDateOfIncorporation
2012-06
CY2019Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-0.367647
CY2019Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.367647
CY2020Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
162400000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
220307000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
112553000
CY2020Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
220344000
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
260000
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
297000
CY2020Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
82358000
CY2020Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
220307000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
112493000
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
47140000
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
112553000
CY2020Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
0
CY2020Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2020Q1 crtx Available For Sale Securities Gross Realized Gains Or Losses
AvailableForSaleSecuritiesGrossRealizedGainsOrLosses
0
CY2020Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20634000
CY2019Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
250000
CY2020Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2020Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
164000
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
987000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
283000
CY2020Q1 crtx Prepaid Insurance Current
PrepaidInsuranceCurrent
278000
CY2020Q1 crtx Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
4776000
CY2019Q4 crtx Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
4517000
CY2020Q1 us-gaap Other Assets Current
OtherAssetsCurrent
954000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
688000
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
366000
CY2020Q1 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
778000
CY2019Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
1261000
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
287000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
96000
CY2020Q1 crtx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
7035000
CY2019Q4 crtx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
4410000
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
53000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
50000
CY2018Q2 crtx Number Of Investors
NumberOfInvestors
1
CY2018Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
0
CY2018Q2 crtx Repurchase Option Percentage
RepurchaseOptionPercentage
1.00
CY2018Q2 crtx Operating Leases Period
OperatingLeasesPeriod
P3Y
CY2019Q2 crtx Operating Lease Payments Paid For Additional Space
OperatingLeasePaymentsPaidForAdditionalSpace
63000
CY2019Q2 crtx Operating Lease Termination Month And Year
OperatingLeaseTerminationMonthAndYear
2021-07
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
0
CY2019Q2 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
false
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
0
CY2020Q1 crtx Operating Lease Future Rent Expense
OperatingLeaseFutureRentExpense
526000
CY2020Q1 crtx Operating Lease Remaining Lease Term On Straight Line Basis
OperatingLeaseRemainingLeaseTermOnStraightLineBasis
P16M
CY2020Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
60000
CY2019Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
0
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
53000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
110000
CY2020Q1 crtx Finance Lease Right Of Use Asset Gross
FinanceLeaseRightOfUseAssetGross
552000
CY2019Q4 crtx Finance Lease Right Of Use Asset Gross
FinanceLeaseRightOfUseAssetGross
559000
CY2020Q1 crtx Accumulated Amortization Of Finance Lease
AccumulatedAmortizationOfFinanceLease
167000
CY2019Q4 crtx Accumulated Amortization Of Finance Lease
AccumulatedAmortizationOfFinanceLease
107000
CY2020Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
385000
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
452000
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2020Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M24D
CY2019Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M6D
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0296
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
41000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
48000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
24000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
113000
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3000
CY2020Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
40700000
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M24D
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1955000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
190000
CY2014Q2 crtx Percentage Of Royalty Rate Of Gross Revenues
PercentageOfRoyaltyRateOfGrossRevenues
0.03
CY2018Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
114437
CY2020Q1 crtx Provision For Income Taxes
ProvisionForIncomeTaxes
0
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3271050
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20250790

Files In Submission

Name View Source Status
0001564590-20-024670-index-headers.html Edgar Link pending
0001564590-20-024670-index.html Edgar Link pending
0001564590-20-024670.txt Edgar Link pending
0001564590-20-024670-xbrl.zip Edgar Link pending
crtx-10q_20200331.htm Edgar Link pending
crtx-20200331.xml Edgar Link completed
crtx-20200331.xsd Edgar Link pending
crtx-20200331_cal.xml Edgar Link unprocessable
crtx-20200331_def.xml Edgar Link unprocessable
crtx-20200331_lab.xml Edgar Link unprocessable
crtx-20200331_pre.xml Edgar Link unprocessable
crtx-ex311_7.htm Edgar Link pending
crtx-ex312_6.htm Edgar Link pending
crtx-ex321_8.htm Edgar Link pending
crtx-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending